{"slug":"therapeutics","open_questions":[{"id":"open_question-therapeutics-convection-enhanced-delivery-3b82e104","title":"Combination therapy","importance_elo":1500,"status":"open","potential_impact_score":0.5,"tractability_score":0.5},{"id":"open_question-therapeutics-convection-enhanced-delivery-0abc85d6","title":"Smart catheters","importance_elo":1500,"status":"open","potential_impact_score":0.5,"tractability_score":0.5},{"id":"open_question-therapeutics-gba-gene-therapy-96a10c72","title":"Self-complementary AAV","importance_elo":1500,"status":"open","potential_impact_score":0.5,"tractability_score":0.5},{"id":"open_question-therapeutics-gba-gene-therapy-1f0a4152","title":"Enhanced capsids","importance_elo":1500,"status":"open","potential_impact_score":0.5,"tractability_score":0.5},{"id":"open_question-therapeutics-gba-gene-therapy-40e0672f","title":"Regulatable expression","importance_elo":1500,"status":"open","potential_impact_score":0.5,"tractability_score":0.5},{"id":"open_question-therapeutics-als-therapeutics-9b6ce13d","title":"Pharmacogenomics","importance_elo":1500,"status":"open","potential_impact_score":0.5,"tractability_score":0.5},{"id":"open_question-therapeutics-nad-precursor-therapy-49402d63","title":"Combination therapies","importance_elo":1500,"status":"open","potential_impact_score":0.5,"tractability_score":0.5},{"id":"open_question-debate-therapeutics-fa1031c7","title":"Does combined maresin analog plus senolytic agent treatment eliminate senescent microglia while preserving non-senescent cells, or does it cause unacceptable off-target toxicity that limits its therap","importance_elo":1500,"status":"open","potential_impact_score":0.75,"tractability_score":0.5},{"id":"open_question-debate-therapeutics-9b1615a0","title":"Can extracellular vesicle-based mitochondrial transfer therapies achieve sufficient brain penetration and neuronal specificity through systemic delivery using current LAMP2B targeting approaches?","importance_elo":1500,"status":"open","potential_impact_score":0.8,"tractability_score":0.3},{"id":"open_question-55a48569-00c3-4dab-8536-5d5af71d9025","title":"What is the optimal dosing regimen for chronic AD treatment?","importance_elo":1500,"status":"open","potential_impact_score":0.5,"tractability_score":0.5},{"id":"open_question-86940f59-55eb-4716-98ed-3f84c87d4838","title":"Optimal dosing**: What is the optimal dose for efficacy while maintaining safety?","importance_elo":1500,"status":"open","potential_impact_score":0.5,"tractability_score":0.5},{"id":"open_question-70d21bf8-c412-44e2-80f0-64e9d9a44092","title":"Clinical outcomes**: Will tau reduction translate to cognitive benefit?","importance_elo":1500,"status":"open","potential_impact_score":0.5,"tractability_score":0.5},{"id":"open_question-a177410d-7578-4131-85b7-be2e036d251e","title":"Long-term safety**: What is the optimal duration of treatment?","importance_elo":1500,"status":"open","potential_impact_score":0.5,"tractability_score":0.5},{"id":"open_question-therapeutics-senolytic-agents-7472f155","title":"Combination trials","importance_elo":1500,"status":"open","potential_impact_score":0.5,"tractability_score":0.5},{"id":"open_question-therapeutics-anti-tau-immunotherapies-836cfc66","title":"Mechanistic understanding","importance_elo":1500,"status":"open","potential_impact_score":0.5,"tractability_score":0.5},{"id":"open_question-therapeutics-senolytic-agents-787945bb","title":"Larger AD trials","importance_elo":1500,"status":"open","potential_impact_score":0.5,"tractability_score":0.5},{"id":"open_question-d2807210-3ef4-4f47-b504-68c5bf277816","title":"Patient selection**: Which patients are most likely to respond?","importance_elo":1500,"status":"open","potential_impact_score":0.5,"tractability_score":0.5},{"id":"open_question-therapeutics-exosome-based-therapeutics-e941c470","title":"Targeting moieties","importance_elo":1500,"status":"open","potential_impact_score":0.5,"tractability_score":0.5},{"id":"open_question-therapeutics-exosome-based-therapeutics-ba0d7929","title":"Cargo loading optimization","importance_elo":1500,"status":"open","potential_impact_score":0.5,"tractability_score":0.5},{"id":"open_question-therapeutics-convection-enhanced-delivery-88d0ca18","title":"Gene therapy","importance_elo":1500,"status":"open","potential_impact_score":0.5,"tractability_score":0.5}],"open_questions_total":20,"knowledge_gaps":[{"id":"gap-debate-20260410-095529-5e98660d","title":"Which specific bacterial strains can restore tight junction integrity while surviving gastric transit and colonizing effectively?","domain":"microbiome therapeutics","status":"open","importance_elo":1000.0},{"id":"gap-debate-20260410-112754-183c16ad","title":"What are the optimal timing and duration parameters for sleep interventions to maximize neuroprotective effects?","domain":"therapeutics","status":"open","importance_elo":1000.0},{"id":"gap-debate-20260410-112805-6d7b6343","title":"What are the optimal sleep restoration protocols for reversing established tau and amyloid pathology?","domain":"therapeutics","status":"open","importance_elo":1000.0},{"id":"gap-pubmed-20260410-170109-8aff6b9b","title":"What determines the specificity and efficiency of mitochondrial uptake by different brain cell types in vivo?","domain":"neurotherapeutics","status":"open","importance_elo":1000.0},{"id":"gap-pubmed-20260410-174005-2f2fc1ab","title":"Why do therapeutic effects persist for 6 months after single ds-cRNA administration?","domain":"neurotherapeutics","status":"open","importance_elo":1000.0},{"id":"gap-pubmed-20260410-181230-4cdd6f61","title":"What mechanisms enable neuropeptide-loaded MSC-EVs to cross the blood-brain barrier via intranasal delivery?","domain":"neurotherapeutics","status":"open","importance_elo":1000.0},{"id":"gap-pubmed-20260410-184305-4ac82631","title":"Why do DNMT1-UHRF1 inhibitors show preferential cytotoxicity in cancer vs non-transformed cells?","domain":"epigenetic therapeutics","status":"open","importance_elo":1000.0},{"id":"gap-pubmed-20260411-072417-76e9c437","title":"How can gene therapy expression be precisely controlled on-demand for the delicate excitatory/inhibitory balance in epilepsy?","domain":"neurotherapeutics","status":"open","importance_elo":1000.0},{"id":"gap-pubmed-20260411-072417-b40dfc53","title":"How can cell-autonomous gene therapy treatments be designed to address epilepsy's complex pathogenic mechanisms?","domain":"neurotherapeutics","status":"open","importance_elo":1000.0}],"gap_count":9,"landscape":null,"hypothesis_count":0,"personas":[{"id":"theorist","name":"Theorist","type":"debater","icon":"🧠","color":"#4fc3f7","debate_count":444},{"id":"skeptic","name":"Skeptic","type":"debater","icon":"⚠️","color":"#ffd54f","debate_count":443},{"id":"domain_expert","name":"Domain Expert","type":"debater","icon":"💊","color":"#81c784","debate_count":427},{"id":"synthesizer","name":"Synthesizer","type":"analyst","icon":"📊","color":"#ce93d8","debate_count":387},{"id":"clinical_trialist","name":"Clinical Trialist","type":"reviewer","icon":"📋","color":"#4dd0e1","debate_count":20},{"id":"computational_biologist","name":"Computational Biologist","type":"analyst","icon":"🧬","color":"#7986cb","debate_count":18},{"id":"ethicist","name":"Ethicist","type":"reviewer","icon":"⚖️","color":"#f48fb1","debate_count":8},{"id":"hongkui-zeng","name":"Hongkui Zeng","type":"debater","icon":"🧬","color":"#66bb6a","debate_count":7},{"id":"medicinal_chemist","name":"Medicinal Chemist","type":"builder","icon":"🧪","color":"#aed581","debate_count":7}]}